This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -28.21% and +2.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Ekta Bagri
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of 31.08% and 30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Bet on These 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
Inovio (INO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
by Zacks Equity Research
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kronos Bio (KRON) delivered earnings and revenue surprises of 11.54% and 35.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -67.86% and 149.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 20.59% and 44.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 92.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 293.75% and 24.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -9.38% and 85.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?
by Zacks Equity Research
Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 223.7% in Inovio (INO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.